Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » Medicine » Medical General » Advances in Medicine and Biology, Volume 1 Chapters » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Embryonic Stem Cells: MHC Expression and Immunogenicity of Stem Cell-Derived Cellular Therapeutics pp. 165-198
Tell A Friend
 
Tell someone you know about this product.
Embryonic Stem Cells: MHC Expression and Immunogenicity of Stem Cell-Derived Cellular Therapeutics pp. 165-198 $100.00
Authors:  (Gesine Fleischmann, Constança Figueiredo, Axel Seltsam, Rainer Blasczyk, Peter A. Horn, Institute for Transfusion Medicine, University Hospital Essen, Germany, and others)
Abstract:
Embryonic stem cells (ESC) represent a theoretically inexhaustible source of precursor cells that can be differentiated into any cell type. These pluripotent, endlessly dividing cells have been hailed as a possible means for treating numerous diseases including degenerative, genetic or malignant diseases, or injury caused by trauma, infection, or inflammation. In addition, ESC are an invaluable research tool to study stem cell development and can serve as a platform to develop and test novel therapies.
Beside the ethical limitations associated with the use of human embryonic stem cells, the application of cellular therapeutics derived from ESC is mainly hindered by two technical hurdles: The risk of tumor formation from undifferentiated ESC on the one hand and rejection of transplanted cells by the host‘s immune system on the other hand.
The emergence of stem cell-based regenerative medicine as a potential therapy for substitution of organs and tissues is therefore intimately correlated with the necessity to inhibit the host immune response to the modified autologous or allogeneic stem cells. One of the most sought after goals in cell as well as tissue and organ transplantation is therefore the ability to induce specific immunologic tolerance to transplantation antigens since this would allow the replacement of host organs or tissues without the need for immunosuppression. In principle, this may be achieved by either altering properties of the host‘s immune system, achieving a state of specific tolerance (or ignorance), or alternatively by altering the properties of the transplanted cells and tissues, making these less immunogenic. Most desirable would be a stable, normal graft function in the complete absence of a requirement for maintenance of immunosuppression. Alternati-vely, the concept of employing tolerogenic strategies to permit graft acceptance with dramatically reduced immunosuppression requirements would already be a significant improvement. 


Available Options:
Version:
This Item Is Currently Unavailable.
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Embryonic Stem Cells: MHC Expression and Immunogenicity of Stem Cell-Derived Cellular Therapeutics pp. 165-198